Kaleido Biosciences - Complete Facility Closure - Clinical Stage Bioscientific Company State-of-the-Art Research and Development Laboratories

Complete Facility Closure - Negotiated Sale Followed by a Global Timed Online Auction Closes: August 23, 2022

Upcoming

DATE

August 23, 2022

LOCATION

Lexington, MA

KALEIDO BIOSCIENCES, INC. – LEXINGTON (BOSTON) MA

COMPLETE FACILITY CLOSURE

GLOBAL ONLINE AUCTION CLOSES: August 23 2022.

We are pleased to announce that Onyx Asset Advisors, LLC. has been formally engaged as the sales agent for the sale of the research and development laboratory assets of a clinical stage biopharmaceutical company, Kaleido Biosciences (“Kaleido”), associated with the complete facility closure of their 40,000 square foot Lexington, MA headquarters.

Kaleido Biosciences, Inc. was a clinical-stage healthcare company, which e focused on leveraging the microbiome organ to treat disease and improve human health. The firm offered microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ’s existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan in January, 2015 and ceased operations in April of 2022.

 

 

In Conjunction with:


Images